In vitro evaluation of TLR4 agonist activity: Formulation effects

被引：41

作者：

Misquith, Ayesha ^{[1
]}

Fung, H. W. Millie ^{[1
]}

Dowling, Quinton M. ^{[1
]}

Guderian, Jeffrey A. ^{[1
]}

Vedvick, Thomas S. ^{[1
]}

Fox, Christopher B. ^{[1
]}

机构：

[1] IDRI, Seattle, WA 98104 USA

来源：

COLLOIDS AND SURFACES B-BIOINTERFACES | 2014年 / 113卷

基金：

美国国家卫生研究院;

关键词：

Vaccine adjuvant formulation; TLR4; agonist; In vitro bioactivity; Particle size; Physicochemical characterization; Glucopyranosyl lipid adjuvant; EFFECTIVE VACCINE; GLA-SE; ENDOTOXIN; COAGULATION; CELLS;

D O I：

10.1016/j.colsurfb.2013.09.006

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Effective in vitro evaluation of vaccine adjuvants would allow higher throughput screening compared to in vivo studies. However, vaccine adjuvants comprise a wide range of structures and formulations ranging from soluble TLR agonists to complex lipid-based formulations. The effects of formulation parameters on in vitro bioactivity assays and the correlations with in vivo adjuvant activity is not well understood. In the present work, we employ the Limulus amebocyte lysate assay and a human macrophage cellular cytokine production assay to demonstrate the differences in in vitro bioactivity of four distinct formulations of the synthetic TLR4 agonist GLA: an aqueous nanosuspension (GLA-AF), an oil-in-water emulsion (GLA-SE), a liposome (GLA-LS), and an alum-adsorbed formulation (GLA-Alum). Furthermore, we demonstrate the importance of the localization of GLA on in vitro potency. By comparing to previous published reports on the in vivo bioactivity of these GLA-containing formulations, we conclude that the most potent activators of the in vitro systems may not be the most potent in vivo adjuvant formulations. Furthermore, we discuss the formulation considerations which should be taken into account when interpreting data from in vitro adjuvant activity assays. (C) 2013 Elsevier B.V. All rights reserved.

引用

页码：312 / 319

页数：8

共 33 条

[11]

Fox CB, 2010, SUBCELL BIOCHEM, V53, P303, DOI 10.1007/978-90-481-9078-2_14

[12] The release and detection of endotoxin from liposomes [J].

Harmon, P ;

CabralLilly, D ;

Reed, RA ;

Maurio, FP ;

Franklin, JC ;

Janoff, A .

ANALYTICAL BIOCHEMISTRY, 1997, 250 (02) :139-146

[13]

Janeway C., 2001, IMMUNOBIOLOGY, V5

[14]

Johnson D.A., 2007, VACCINE ADJUVANTS DE

[15]

LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265

[16]

LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P337

[17] A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2-A GLURP-MSP3 fusion protein malaria vaccine candidate [J].

Lousada-Dietrich, Susana ;

Jogdand, Prajakta S. ;

Jepsen, Soren ;

Pinto, Vera V. ;

Ditlev, Sisse B. ;

Christiansen, Michael ;

Larsen, Severin Olesen ;

Fox, Christopher B. ;

Raman, Vanitha S. ;

Howard, Randall F. ;

Vedvick, Thomas S. ;

Ireton, Gregory ;

Carter, Darrick ;

Reed, Steven G. ;

Theisen, Michael .

VACCINE, 2011, 29 (17) :3284-3292

[18] Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model [J].

Ma, Yifan ;

Poisson, Louis ;

Sanchez-Schmitz, Guzman ;

Pawar, Santosh ;

Qu, Chunfeng ;

Randolph, Gwendalyn J. ;

Warren, William L. ;

Mishkin, Eric M. ;

Higbee, Russell G. .

IMMUNOLOGY, 2010, 130 (03) :374-387

[19]

McNeil SE, 2011, METHODS MOL BIOL, V697, P9, DOI 10.1007/978-1-60327-198-1_2

[20]

Neun BW, 2011, METHODS MOL BIOL, V697, P121, DOI 10.1007/978-1-60327-198-1_12

← 1 2 3 4 →